• PN: B116660

COMPONENTS

45x Ab-conjugated beads (S5P8- human MIA Ab-bead). PN: B116660A. One vial containing 100 µL of anti-human MIA conjugated to AimPlex Bead S5P8.

25x Biotin-detection Ab (human MIA Biotin-dAb). PN: B116660B. One vial containing 100 µL of biotinylated anti-human MIA.

Lyophilized Standard Mix-Human Group 10, Panel B, 7-Plex. PN: HG1007B. One vial containing lyophilized recombinant Lymphotactin, MIA, Midkine, NOV, NRG1-beta1, sTACI, and sTRAIL. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human Human MIA/CD-RAP. Can be multiplexed with other analytes in Human Group 10.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 10 pg/mL

Quantitation range:

LLOQ: < 20 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 10: Negligible

Sample volume: 15 µL/test

Description:

The protein from human melanoma cell lines and tumors is called melanoma inhibitory activity (MIA) and the protein from primary bovine chondrocytes and cartilaginous tissues is called cartilage-derived retinoic acid-sensitive protein (CD-RAP). Melanoma Inhibitory Activity (MIA) elicits growth inhibition on melanoma cells in vitro as well as some other neuroectodermal tumors, including gliomas. Diseases associated with MIA include skin melanoma and oral squamous cell carcinoma.

References:

1.      Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U (Nov 1994). "Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA". Cancer Res 54 (21): 5695–701. PMID 7923218.

2.      Koehler MR, Bosserhoff A, von Beust G, Bauer A, Blesch A, Buettner R, Schlegel J, Bogdahn U, Schmid M (Sep 1996). "Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH)". Genomics 35 (1): 265–7. doi:10.1006/geno.1996.0352. PMID 8661134.

3.      Bosserhoff AK, Kaufmann M, Kaluza B, et al. (August 1997). "Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma". Cancer Res. 57 (15): 3149–53. PMID 9242442.